查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1833578

2032年口服抗生素市場預測：按藥物類別、活性頻譜、適應症、病患小組、通路、劑型和地區進行的全球分析

Oral Antibiotics Market Forecasts to 2032 - Global Analysis By Drug Class, Spectrum of Activity, Indication, Patient Group, Distribution Channel, Formulation Type and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球口服抗生素市場預計在 2025 年達到 514 億美元，到 2032 年將達到 830.9 億美元，預測期內的複合年成長率為 7.1%。

口服抗生素是口服藥物，用於治療體內細菌感染。抗生素的作用機轉是消滅細菌或抑制其生長，增強免疫系統並控制疾病。口服抗生素有膠囊、錠劑或懸浮液等劑型，常用於治療感染疾病、感染疾病、尿道感染及胃腸道感染疾病等疾病。使用口服抗生素時，正確的醫療指導至關重要，這樣才能達到預期效果並最大限度地降低抗生素抗藥性的風險。

據世界衛生組織 (WHO) 稱，全球細菌性疾病負擔日益加重，對有效治療方法的需求也日益成長。

患者便利且經濟高效

口服抗生素因其給藥方便、治療成本低而日益受到偏好。與靜脈注射不同，口服製劑無需住院，是門診治療的理想選擇。這種便利性尤其有利於慢性感染疾病和長期治療。藥物輸送系統的技術進步正在提高生物有效性和患者依從性。新興趨勢包括緩釋性膠囊和兒科口味改良混懸液。隨著醫療保健系統優先考慮具有成本效益的解決方案，口服抗生素在已開發市場和新興市場都越來越受歡迎。

副作用和安全問題

胃腸不適、過敏反應和微生物組崩壞是患者和臨床醫生通用關注的問題。監管機構正在加強安全標準，強制進行大規模臨床試驗和上市後監測。人工智慧與藥物安全檢測的整合有助於更有效地檢測不利事件。小型製藥公司往往難以應對合規成本和不斷變化的安全通訊協定。這些挑戰可能會延遲產品核准，並限制口服抗生素領域的創新。

新藥開發

抗生素抗藥性病原體的增加推動了對下一代口服抗生素的需求。製藥公司正在投資研發具有標靶機制的新型化合物，以克服抗藥性。基因組學和人工智慧驅動的藥物研發正在加速開發平臺。生技新興企業正在探索微生物友善製劑和窄頻譜藥物，以最大限度地減少附帶損害。監管機構正在為突破性治療方法提供快速核准和獎勵。這種格局為製劑、給藥和治療標靶的創新創造了巨大的機會。

來自替代療法的競爭

噬菌體療法、免疫調節劑和益生菌等治療方法在感染控制方面正日益受到臨床關注。醫院正在採用精準醫療方法，以減少對廣譜抗生素的依賴。數位健康平台正在促進早期診斷和預防性護理，從而可能降低抗生素需求。供應鏈中斷和原料短缺進一步加劇了競爭壓力。因此，口服抗生素市場正面臨非抗生素療法和先進生技藥品日益激烈的競爭。

COVID-19的影響：

疫情顯著改變了抗生素處方模式，導致門診量減少，非緊急治療延誤。封鎖措施擾亂了生產和全球供應鏈，導致關鍵口服藥物短缺。然而，這場危機加速了數位醫療的普及，包括遠距諮詢和電子處方箋。監管機構已推出緊急通訊協定，以確保持續獲得​​基本抗生素。疫情後的策略如今強調分散生產和彈性分銷網路。對抗菌藥物管理的重新關注正在重塑口服抗生素的未來使用。

預計頻譜部分將成為預測期內最大的部分

由於頻譜抗生素在各種感染疾病中的廣泛適用性，預計在預測期內將佔據最大的市場佔有率。在病原體尚未確定的情況下，這些藥物是經驗性治療的首選。技術進步使得廣譜頻譜靶向性更強，從而降低了抗藥性風險。醫院和診所正在大量使用這些藥物來治療急性和慢性感染疾病。聯合治療和雙促效劑的創新正在增強其臨床效用。除了改良的診斷工具外，頻譜抗生素仍然是第一線治療通訊協定的核心。

預計預測期內，懸吊部分將實現最高的複合年成長率

由於懸浮液適用於兒童和老年族群，預計在預測期內將達到最高成長率。這些製劑透過靈活的劑量和更佳的偏好提高了患者的依從性。遮罩味和穩定性技術的進步正在擴大其治療範圍。製造商正在開發即用型懸浮液製劑，以簡化藥房運作。門診和家庭護理的興起推動了對液體抗生素的需求。隨著個人化醫療的發展，懸浮液正成為客製化給藥策略中不可或缺的一部分。

比最大的地區

在預測期內，受醫療基礎設施擴張和感染率上升的推動，亞太地區預計將佔據最大的市場佔有率。印度、中國和日本等國家正在投資國內藥品生產和抗生素管理計畫。政府正在舉措該地區的可負擔醫療服務和技術創新。該地區正在迅速普及數位健康平台和人工智慧輔助診斷技術。跨國公司與本地製造商之間的策略聯盟正在加強市場滲透。在中階不斷壯大和醫療保健意識不斷提升的推動下，亞太地區將繼續成為重要的成長引擎。

複合年成長率最高的地區：

預計北美地區在預測期內的複合年成長率最高。美國和加拿大在口服給藥和抗藥性監測方面處於領先地位。監管機構正在簡化新型抗生素和配方改良的核准途徑。醫院正在整合電子處方和基於人工智慧的感染追蹤技術，以最佳化抗生素的使用。該地區受益於強大的報銷框架和門診治療的高採用率。隨著抗菌素抗藥性成為公共衛生優先事項，北美正在引領全球抗生素創新的步伐。

免費客製化服務：

此報告的訂閱者可以選擇以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球口服抗生素市場（依藥物類別）

  • 青黴素
  • Aminoglycosides
  • 頭孢菌素類
  • 磺胺類藥物
  • 大環內酯類
  • Fluoroquinolones
  • 四環黴素
  • 其他藥物類別

6. 全球口服抗生素市場（依活性頻譜）

  • 頻譜抗生素
  • 窄效抗生素

7. 全球口服抗生素市場（按適應症）

  • 呼吸道感染疾病
  • 尿道感染
  • 牙齒感染疾病
  • 皮膚和軟組織感染疾病
  • 性行為感染傳染病
  • 胃腸道感染疾病
  • 其他適應症

8. 全球口服抗生素市場（依病患小組）

  • 成人
  • 老年人
  • 孩子們

9. 全球口服抗生素市場（依通路）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

10. 全球口服抗生素市場（按劑型）

  • 藥片
  • 粉末
  • 膠囊
  • 暫停

11. 全球口服抗生素市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章：企業概況

  • Pfizer Inc.
  • Bristol Myers Squibb
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc（GSK）
  • Astellas Pharma Inc.
  • Novartis AG
  • Cipla Ltd.
  • Sanofi
  • Roche Holding AG
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • Abbott Laboratories
Product Code: SMRC31411

According to Stratistics MRC, the Global Oral Antibiotics Market is accounted for $51.40 billion in 2025 and is expected to reach $83.09 billion by 2032 growing at a CAGR of 7.1% during the forecast period. Oral antibiotics are drugs administered orally to treat bacterial infections in the body. They function by eliminating bacteria or hindering their multiplication, supporting the immune system in controlling illness. Offered as capsules, tablets, or liquid suspensions, they are frequently used for conditions like respiratory, skin, urinary tract, and digestive infections. Proper medical guidance is essential when using oral antibiotics to achieve desired outcomes and minimize the risk of antibiotic resistance.

According to the World Health Organization, the global burden of bacterial diseases continues to escalate, prompting a heightened demand for effective treatment options.

Market Dynamics:

Driver:

Patient convenience and cost-effectiveness

The growing preference for oral antibiotics stems from their ease of administration and reduced treatment costs. Unlike intravenous therapies, oral formulations eliminate the need for hospital visits, making them ideal for outpatient care. This convenience is especially beneficial for chronic infections and long-term therapies. Technological advancements in drug delivery systems are enhancing bioavailability and patient adherence. Emerging trends include extended-release capsules and taste-masked suspensions for pediatric use. As healthcare systems prioritize cost-effective solutions, oral antibiotics are gaining traction across both developed and emerging markets.

Restraint:

Adverse side effects and safety concerns

Gastrointestinal disturbances, allergic reactions, and microbiome disruption are common concerns among patients and clinicians. Regulatory agencies are tightening safety standards, requiring extensive clinical trials and post-marketing surveillance. The integration of AI in pharmacovigilance is helping detect adverse events more efficiently. Smaller pharmaceutical firms often struggle with compliance costs and evolving safety protocols. These challenges can delay product approvals and limit innovation in the oral antibiotics space.

Opportunity:

Novel drug development

The rise of antibiotic-resistant pathogens is fueling demand for next-generation oral antibiotics. Pharmaceutical companies are investing in novel compounds with targeted mechanisms to overcome resistance. Advances in genomics and AI-driven drug discovery are accelerating the development pipeline. Biotech startups are exploring microbiome-friendly formulations and narrow-spectrum agents to minimize collateral damage. Regulatory bodies are offering fast-track approvals and incentives for breakthrough therapies. This landscape presents significant opportunities for innovation in formulation, delivery, and therapeutic targeting.

Threat:

Competition from alternative therapies

Therapies such as phage therapy, immunomodulators, and probiotics are gaining clinical interest for infection management. Hospitals are adopting precision medicine approaches that reduce reliance on broad-spectrum antibiotics. Digital health platforms are promoting early diagnosis and preventive care, potentially lowering antibiotic demand. Supply chain disruptions and raw material shortages further intensify competitive pressures. Thus, the oral antibiotics market faces increasing competition from non-antibiotic treatments and advanced biologics.

Covid-19 Impact:

The pandemic significantly altered antibiotic prescribing patterns, with reduced outpatient visits and delayed non-urgent treatments. Lockdowns disrupted manufacturing and global supply chains, leading to shortages in key oral formulations. However, the crisis accelerated digital health adoption, including remote consultations and e-prescriptions. Regulatory agencies introduced emergency protocols to ensure continued access to essential antibiotics. Post-pandemic strategies now emphasize decentralized production and resilient distribution networks. The renewed focus on antimicrobial stewardship is reshaping the future of oral antibiotic usage.

The spectrum segment is expected to be the largest during the forecast period

The spectrum segment is expected to account for the largest market share during the forecast period, due to its broad applicability across various infections. These drugs are favored for empirical therapy when pathogen identification is pending. Technological advancements are enabling more precise spectrum targeting, reducing resistance risks. Hospitals and clinics rely heavily on these formulations for both acute and chronic infections. Innovations in combination therapies and dual-action agents are reinforcing their clinical utility. As diagnostic tools improve, spectrum antibiotics remain central to frontline treatment protocols.

The suspensions segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the suspensions segment is predicted to witness the highest growth rate, driven by their suitability for pediatric and geriatric populations. These formulations offer flexible dosing and improved palatability, enhancing patient compliance. Advances in taste-masking and stability technologies are expanding their therapeutic range. Manufacturers are developing ready-to-use suspensions to streamline pharmacy operations. The rise in outpatient care and home-based treatments is boosting demand for liquid antibiotics. As personalized medicine gains momentum, suspensions are becoming integral to tailored dosing strategies.

Region with largest share:

During the forecast period, the Asia Pacificregion is expected to hold the largest market share, supported by expanding healthcare infrastructure and rising infection rates. Countries like India, China, and Japan are investing in domestic pharmaceutical production and antibiotic stewardship programs. Government initiatives are promoting affordable access and local innovation. The region is witnessing rapid adoption of digital health platforms and AI-assisted diagnostics. Strategic collaborations between global firms and regional manufacturers are enhancing market penetration. With a growing middle class and increasing healthcare awareness, Asia Pacific remains a key growth engine.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by robust R&D and advanced healthcare systems. The U.S. and Canada are pioneering innovations in oral drug delivery and resistance monitoring. Regulatory bodies are streamlining approval pathways for novel antibiotics and reformulations. Hospitals are integrating electronic prescribing and AI-based infection tracking to optimize antibiotic use. The region benefits from strong reimbursement frameworks and high adoption of outpatient therapies. As antimicrobial resistance becomes a public health priority, North America is setting the pace for global antibiotic innovation.

Key players in the market

Some of the key players in Oral Antibiotics Market include Pfizer Inc., Bristol Myers Squibb, Merck & Co., Inc., Eli Lilly and Company, GlaxoSmithKline plc (GSK), AstellasPharma Inc., Novartis AG, Cipla Ltd., Sanofi, Roche Holding AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Bayer AG, Takeda Pharmaceutical Company Limited, and Abbott Laboratories.

Key Developments:

In September2025, Pfizer Inc. and Metsera, Inc. announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a portfolio of differentiated oral and injectable incretin, non-incretin and combination therapy candidates with potential best-in-class efficacy and safety profiles.

In July2025, The Bristol Myers Squibb-Pfizer Alliance announced a new direct-to-patient option for purchasing Eliquis(R) (apixaban) via our Alliance's patient resource Eliquis 360 Support. The offering provides an opportunity for uninsured, underinsured, or self-pay patients to significantly lower their out-of-pocket costs for this critical medicine. Eliquis is relied upon by millions of Americans daily and this program will provide a simple and transparent way to access it.

Drug Classes Covered:

  • Penicillins
  • Aminoglycosides
  • Cephalosporins
  • Sulfonamides
  • Macrolides
  • Fluoroquinolones
  • Tetracyclines
  • Other Drug Classes

Spectrum of Activities Covered:

  • Broad-Spectrum Antibiotics
  • Narrow-Spectrum Antibiotics

Indications Covered:

  • Respiratory Tract Infections
  • Urinary Tract Infections
  • Dental Infections
  • Skin and Soft Tissue Infections
  • Sexually Transmitted Infections
  • Gastrointestinal Infections
  • Other Indications

Patient Groups Covered:

  • Adults
  • Geriatrics
  • Pediatrics

Distribution Channels Covered:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Formulation Types Covered:

  • Tablets
  • Powders
  • Capsules
  • Suspensions

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Oral Antibiotics Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Penicillins
  • 5.3 Aminoglycosides
  • 5.4 Cephalosporins
  • 5.5 Sulfonamides
  • 5.6 Macrolides
  • 5.7 Fluoroquinolones
  • 5.8 Tetracyclines
  • 5.9 Other Drug Classes

6 Global Oral Antibiotics Market, By Spectrum of Activity

  • 6.1 Introduction
  • 6.2 Broad-Spectrum Antibiotics
  • 6.3 Narrow-Spectrum Antibiotics

7 Global Oral Antibiotics Market, By Indication

  • 7.1 Introduction
  • 7.2 Respiratory Tract Infections
  • 7.3 Urinary Tract Infections
  • 7.4 Dental Infections
  • 7.5 Skin and Soft Tissue Infections
  • 7.6 Sexually Transmitted Infections
  • 7.7 Gastrointestinal Infections
  • 7.8 Other Indications

8 Global Oral Antibiotics Market, By Patient Group

  • 8.1 Introduction
  • 8.2 Adults
  • 8.3 Geriatrics
  • 8.4 Pediatrics

9 Global Oral Antibiotics Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Online Pharmacies
  • 9.4 Retail Pharmacies

10 Global Oral Antibiotics Market, By Formulation Type

  • 10.1 Introduction
  • 10.2 Tablets
  • 10.3 Powders
  • 10.4 Capsules
  • 10.5 Suspensions

11 Global Oral Antibiotics Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Pfizer Inc.
  • 13.2 Bristol Myers Squibb
  • 13.3 Merck & Co., Inc.
  • 13.4 Eli Lilly and Company
  • 13.5 GlaxoSmithKline plc (GSK)
  • 13.6 Astellas Pharma Inc.
  • 13.7 Novartis AG
  • 13.8 Cipla Ltd.
  • 13.9 Sanofi
  • 13.10 Roche Holding AG
  • 13.11 Johnson & Johnson
  • 13.12 Teva Pharmaceutical Industries Ltd.
  • 13.13 Bayer AG
  • 13.14 Takeda Pharmaceutical Company Limited
  • 13.15 Abbott Laboratories

List of Tables

  • Table 1 Global Oral Antibiotics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Oral Antibiotics Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 3 Global Oral Antibiotics Market Outlook, By Penicillins (2024-2032) ($MN)
  • Table 4 Global Oral Antibiotics Market Outlook, By Aminoglycosides (2024-2032) ($MN)
  • Table 5 Global Oral Antibiotics Market Outlook, By Cephalosporins (2024-2032) ($MN)
  • Table 6 Global Oral Antibiotics Market Outlook, By Sulfonamides (2024-2032) ($MN)
  • Table 7 Global Oral Antibiotics Market Outlook, By Macrolides (2024-2032) ($MN)
  • Table 8 Global Oral Antibiotics Market Outlook, By Fluoroquinolones (2024-2032) ($MN)
  • Table 9 Global Oral Antibiotics Market Outlook, By Tetracyclines (2024-2032) ($MN)
  • Table 10 Global Oral Antibiotics Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 11 Global Oral Antibiotics Market Outlook, By Spectrum of Activity (2024-2032) ($MN)
  • Table 12 Global Oral Antibiotics Market Outlook, By Broad-Spectrum Antibiotics (2024-2032) ($MN)
  • Table 13 Global Oral Antibiotics Market Outlook, By Narrow-Spectrum Antibiotics (2024-2032) ($MN)
  • Table 14 Global Oral Antibiotics Market Outlook, By Indication (2024-2032) ($MN)
  • Table 15 Global Oral Antibiotics Market Outlook, By Respiratory Tract Infections (2024-2032) ($MN)
  • Table 16 Global Oral Antibiotics Market Outlook, By Urinary Tract Infections (2024-2032) ($MN)
  • Table 17 Global Oral Antibiotics Market Outlook, By Dental Infections (2024-2032) ($MN)
  • Table 18 Global Oral Antibiotics Market Outlook, By Skin and Soft Tissue Infections (2024-2032) ($MN)
  • Table 19 Global Oral Antibiotics Market Outlook, By Sexually Transmitted Infections (2024-2032) ($MN)
  • Table 20 Global Oral Antibiotics Market Outlook, By Gastrointestinal Infections (2024-2032) ($MN)
  • Table 21 Global Oral Antibiotics Market Outlook, By Other Indications (2024-2032) ($MN)
  • Table 22 Global Oral Antibiotics Market Outlook, By Patient Group (2024-2032) ($MN)
  • Table 23 Global Oral Antibiotics Market Outlook, By Adults (2024-2032) ($MN)
  • Table 24 Global Oral Antibiotics Market Outlook, By Geriatrics (2024-2032) ($MN)
  • Table 25 Global Oral Antibiotics Market Outlook, By Pediatrics (2024-2032) ($MN)
  • Table 26 Global Oral Antibiotics Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 27 Global Oral Antibiotics Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 28 Global Oral Antibiotics Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 29 Global Oral Antibiotics Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 30 Global Oral Antibiotics Market Outlook, By Formulation Type (2024-2032) ($MN)
  • Table 31 Global Oral Antibiotics Market Outlook, By Tablets (2024-2032) ($MN)
  • Table 32 Global Oral Antibiotics Market Outlook, By Powders (2024-2032) ($MN)
  • Table 33 Global Oral Antibiotics Market Outlook, By Capsules (2024-2032) ($MN)
  • Table 34 Global Oral Antibiotics Market Outlook, By Suspensions (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.